Form D · Biotechnology

Revitope Oncology, Inc.

San Francisco, CA · CIK 0001667518

Offering snapshot reported Sep 14, 2016 · SEC filing

Reported sold
$8.2M
Offering amount: $8.2M
Investors reported
12
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 10, 2016
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$4.1M$8.2MFeb 19, 2016: $5,200,000.00Feb 19, 2016Sep 14, 2016: $8,200,000.00Sep 14, 2016

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$5,200,000 → $8,200,000

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 14, 2016Amendment$8,200,000$3,000,000vs Feb 19, 201612SEC filing
Feb 19, 2016Initial$5,200,000No comparison12SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-257799

Source: Form D, filed Sep 14, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Andrew Allen Director, Executive
Julie Cherrington Director, Executive
Mark Cobbold Director
Peter Joost Director
Raj Mehta Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
953 Indiana St
San Francisco, CA, 94107